1. Swigris JJ et al. Eur Respir Rev 2018;27(150).
2. Flaherty KR et al. N Engl J Med 2019;381:1718–27.
3. Burckhardt CS et al. Res Nurs Health 1989;12:347–54.
4. Flanagan JC. Am Psychol 1978;33:138–47.

The INBUILD trial was funded by Boehringer Ingelheim. Editorial and formatting assistance, supported financially by Boehringer Ingelheim, was provided by Julie Fleming and Wendy Morris of FleishmanHillard Fishburn, London, UK during preparation of this e-poster. The authors were fully responsible for all content and editorial decisions, were involved at all stages of e-poster development and have approved the final version. Boehringer Ingelheim was given the opportunity to review the e-poster for medical and scientific accuracy as well as intellectual property considerations. The authors received no direct compensation related to the development of this poster. Jeffrey J. Swigris has received grant funding for investigator-initiated studies and honoraria for giving unbranded talks on pulmonary fibrosis from Genentech and Boehringer Ingelheim. Jeffrey Swigris is the developer of the L-PF questionnaire and is working with a professional agency to move it through the FDA qualifications process. Kevin R. Flaherty reports grants and personal fees from Boehringer Ingelheim and Roche/Genentech; and personal fees from Bellerophon Therapeutics, Blade Therapeutics, Celgene, FibroGen, Respivant, Sanofi Genzyme, and Veracyte.